News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ACC 2025 Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE Caitlin E. Cox April 02, 2025
News Conference News SCAI 2023 SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year L.A. McKeown May 31, 2023
News Conference News EuroPCR 2023 Many ACS Patients With Occlusions Are Falling Through the Cracks Todd Neale May 19, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News TCT 2022 PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI Shelley Wood September 22, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2019 Young MI Patients’ Ischemic Risk Extends at Least Two Decades Caitlin E. Cox September 06, 2019
News Conference News ESC 2019 Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS Yael L. Maxwell August 31, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News CRT 2018 Acute MI Patients With Paraplegia Rarely Get Revascularization, Face Higher Risk of Death Shelley Wood March 05, 2018
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
News Conference News ESC 2017 Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets Michael O'Riordan August 30, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Conference News ACC 2017 Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term Michael O'Riordan March 10, 2017